Holen Sie sich die Stockscreener-App
355.23
0.29%
-1.03
Handel nachbörslich:
355.23
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Sickle Cell Anemia Testing & Screening Industry Trends & Growth - SNS Insider
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value? - Sahm
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript - aol.com
Bio-Rad Laboratories (NYSE:BIO) Hits New 52-Week HighHere's What Happened - MarketBeat
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bio-Rad Laboratories (BIO) Stock Analysis: Exploring a Potentially Overvalued Healthcare Giant - DirectorsTalk Interviews
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus - Yahoo Finance
Technical Reactions to BIO Trends in Macro Strategies - Stock Traders Daily
Assenagon Asset Management S.A. Acquires 85,393 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at 352.86 USD - Investing.com
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
US$329That's What Analysts Think Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Worth After These Results - Moomoo
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $390 - Moomoo
Bio-Rad's FCPA Review Gets Picked Over at Trial - Law.com
Bio-Rad Laboratories, Inc. $BIO Shares Bought by California State Teachers Retirement System - marketbeat.com
BIO-RAD LABORATORIES, INC. : WELLS FARGO RAISES TARGET PRICE TO $330 FROM $310 - webull.com
BIO Maintained by Citigroup -- Price Target Raised to $330 - GuruFocus
Is Bio-Rad Laboratories Inc (BIO) Overvalued After 4.5% Rally? G - GuruFocus
Citigroup Increases Bio-Rad Laboratories (NYSE:BIO) Price Target to $330.00 - MarketBeat
BIO Maintains Rating by Wells Fargo -- Price Target Raised to $3 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Bio-Rad Laboratories (NYSE:BIO) Stock - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Sets New 52-Week High on Earnings Beat - marketbeat.com
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BIO SWOT Analysis: Financial Resilience Amidst Market Challenges Revealed in 10-Q Filing - GuruFocus
AUG 04 (REUTERS)BIO-RAD Q2 EPS USD 13.85. - Moomoo
Amundi Has $10.81 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ... By GuruFocus - Investing.com Canada
BIO Looks 4.8% Overvalued on GF Value™ Amid Restructuring Plans - GuruFocus
Bio-Rad Laboratories Q2 Earnings Call Highlights - MarketBeat
Bio-Rad: Q2 Earnings Snapshot - Barchart.com
Is Bio-Rad Laboratories Inc (BIO) Overvalued After Q2 Earnings B - GuruFocus
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates - finance.yahoo.com
Bio-Rad Laboratories, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Bio-Rad tops Q2 2026 estimates, shares fall after hours - Investing.com
BIO Looks 4.8% Overvalued on GF Value™ as Growth Momentum Shines - GuruFocus
BIO Looks 4.8% Overvalued on GF Value™ as Market Weighs 2026 Gui - GuruFocus
Bio-Rad Laboratories Q2 Adjusted Earnings Rise, Revenue Falls - marketscreener.com
Q2 2026 Bio Rad Laboratories Inc Earnings Call Transcript - GuruFocus
Bio-Rad Laboratories (BIO) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Bio-Rad Laboratories (NYSE:BIO) Releases Earnings Results, Beats Estimates By $0.87 EPS - MarketBeat
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q2 Revenue $651.0M, vs. FactSet Est of $624.0M - marketscreener.com
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Posts Q2 Adjusted EPS $2.62 per Share, vs. FactSet Est of $1.75 - marketscreener.com
BIO-RAD LABORATORIES, INC. 2Q 2026: Revenue $651M, EPS $13.85— 10-Q Summary - TradingView
Bio-Rad Laboratories (NYSE: BIO) Q2 profit offset by H1 fair-value losses - Stock Titan
Press Release: Bio-Rad Reports Second-Quarter 2026 Financial Results - Moomoo
Bio-Rad earnings up next: Can diagnostics stabilize amid headwinds? By Investing.com - Investing.com Nigeria
Bio-Rad earnings up next: Can diagnostics stabilize amid headwinds? - Investing.com
BIO: Q2 revenue flat year-over-year, digital PCR strong, restructuring targets $30–$35M savings by 2027 - TradingView
Arrowstreet Capital Limited Partnership Invests $4.39 Million in Bio-Rad Laboratories, Inc. $BIO - marketbeat.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a 8.75% Potential Downside Amidst Strong Sector Position - DirectorsTalk Interviews
18,290 Shares in Bio-Rad Laboratories, Inc. $BIO Bought by Lazard Asset Management LLC - MarketBeat
Bio-Rad Laboratories Inc (BIO) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Bio-Rad Laboratories (NYSE: BIO) exec vests 246 RSUs, withholds shares - Stock Titan
BIO|Bio Rad Laboratories Inc|Price:316.410|Chg%:+1.950 - TradingKey
Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Hound Partners LLC - MarketBeat
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):